预约演示
更新于：2026-08-23
Fluticasone Propionate
丙酸氟替卡松
更新于：2026-08-23
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1990-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
关联
525
项与 丙酸氟替卡松 相关的临床试验NCT07675252
A Multicenter Clinical Study on Efficacy and Safety of Fluticasone Propionate Nebulized Suspension in the Treatment of Wheezing Diseases in Infants Aged 0-24 Months
NCT07664527
A Proof-of-Concept Study of a Novel Method for Removal of Residual Oropharyngeal Inhaled Corticosteroid Deposits in Asthma
ACTRN12626000870358
Optimising intranasal corticosteroid delivery for Tamariki with Otitis Media with Effusion (OME): A randomised crossover trial comparing fluticasone metered-dose inhaler (MDI) versus aqueous fluticasone nasal spray.
100 项与 丙酸氟替卡松 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的专利（医药）
登录后查看更多信息
4,347
项与 丙酸氟替卡松 相关的文献（医药）2026-08-01RESPIRATORY MEDICINE
Multidimensional evaluation of clinical symptoms, pulmonary function, and imaging in long-term treatment of infants with post-infectious bronchiolitis obliterans
Article
作者: Zhang, Lan ; Pan, Jia-Hua ; He, Li-Ting
OBJECTIVE:
To investigate efficacy of standardized treatment for post-infectious bronchiolitis obliterans (PIBO) in infants and young children by evaluating changes in pulmonary function, and high-resolution computed tomography (HRCT) before and after treatment.
METHODS:
Thirty infants diagnosed with PIBO were treated with a two-phase protocol consisting of an intensive phase and a maintenance phase, including budesonide, azithromycin, montelukast, fluticasone propionate, and terbutaline sulfate. Pulmonary function was evaluated using TPTEF/TE, VPEF/VE, and impulse oscillometry (IOS). Imaging evaluation was performed using HRCT.
RESULTS:
Daytime respiratory symptoms significantly improved after 3 months of treatment (P < 0.05). Nocturnal symptoms and exercise-related limitations showed significant improvement after 6 months (P < 0.05) and 9 months (P < 0.05), respectively. The frequency of respiratory tract infections was significantly reduced after 12 months of continuous treatment (P < 0.05). Pulmonary function indices demonstrated significant improvement by the 9th month (P < 0.05). HRCT scores improved significantly, decreasing from 6 ± 1.08 at baseline to 4.5 ± 1.98 after 12 months of treatment (P < 0.05). Mosaic perfusion significantly improved at 6 months (P < 0.05), while emphysematous changes required 9 months of treatment to show significant improvement (P < 0.05). Structural abnormalities such as bronchiectasis, bronchial wall thickening, atelectasis, and peribronchial vascular bundle changes showed partial improvement after 12 months, but these differences did not reach statistical significance (P > 0.05).
CONCLUSION:
Standardized treatment for PIBO should be maintained for at least 9-12 months to achieve significant improvements in clinical symptoms, pulmonary function, and HRCT findings.
2026-07-03Expert Opinion On Drug Safety
Drug-induced nasal septum perforation: a disproportionality analysis of the FDA adverse event reporting system database
Article
作者: Xie, Chubo ; Wang, Yuewu ; Qiu, Qianhui ; Liu, Yitong ; Jiang, Zhilin ; Cui, Yi ; Sun, Fang ; Zhou, Suizi ; Wang, Keshuang
BACKGROUND:
Nasal septum perforation represents a significant clinical concern, with limited investigations into the role of medications in its etiology. This study utilizes the FDA Adverse Event Reporting System (FAERS) database to identify the drugs associated with nasal septum perforation and assess their risk.
RESEARCH DESIGN AND METHODS:
This retrospective pharmacovigilance study analyzed drug-induced nasal septum perforation data from January 2004 to December 2023. Disproportionality analysis using reporting odds ratio (ROR) assessed drug associations with nasal septum perforation.
RESULTS:
For 552 identified cases, the most commonly reported drugs were bevacizumab (n = 56), fluticasone propionate (n = 50), methotrexate (n = 34), hydrocodone and acetaminophen (n = 22), and paclitaxel (n = 17). Twenty-six drugs showed positive risk signals, with the top five being azelastine hydrochloride and fluticasone propionate (ROR = 173.82), beclomethasone dipropionate (ROR = 90.91), oxymetazoline (ROR = 53.77), desmopressin (ROR = 51.43), and leucovorin (ROR = 42.83). Intriguingly, 18 of these drugs did not list nasal septum perforation as a known side effect.
CONCLUSION:
This study provides a comprehensive overview of drug-induced nasal septum perforation from a pharmacovigilance perspective, highlighting the need for further research to clarify these associations and update drug safety information to reduce patient risk.
2026-07-01AMERICAN JOURNAL OF NURSING
True generic of Flovent HFA inhaler now approved
Article
作者: Aschenbrenner, Diane S
802
项与 丙酸氟替卡松 相关的新闻（医药）2026-08-20
·药圈头条
100 项与 丙酸氟替卡松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎 | 美国 | 2024-03-15 | |
| 鼻塞 | 美国 | 2014-07-23 | |
| 打喷嚏 | 美国 | 2014-07-23 | |
| 特应性皮炎 | 美国 | 2005-03-31 | |
| 皮炎 | 日本 | 2001-10-02 | |
| 接触性皮炎 | 日本 | 2001-10-02 | |
| 脂溢性皮炎 | 日本 | 2001-10-02 | |
| 湿疹 | 日本 | 2001-10-02 | |
| 红斑 | 日本 | 2001-10-02 | |
| 扁平苔藓 | 日本 | 2001-10-02 | |
| 盘状红斑狼疮 | 日本 | 2001-10-02 | |
| 鼻息肉 | 日本 | 2001-10-02 | |
| 神经性皮炎 | 日本 | 2001-10-02 | |
| 痒疹 | 日本 | 2001-10-02 | |
| 瘙痒 | 日本 | 2001-10-02 | |
| 银屑病 | 日本 | 2001-10-02 | |
| 常年性变应性鼻炎 | 中国 | 2000-06-16 | |
| 常年性变应性鼻炎 | 中国 | 2000-06-16 | |
| 季节性过敏性鼻炎 | 中国 | 2000-06-16 | |
| 哮喘 | 美国 | 1996-03-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 无鼻息肉的慢性鼻窦炎 | 临床3期 | 美国 | 2025-07-28 | |
| 慢性哮喘 | 临床3期 | 希腊 | 2020-12-09 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 美国 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 澳大利亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 保加利亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 捷克 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 格鲁吉亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 新西兰 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 波兰 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 罗马尼亚 | 2019-06-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 31 | 窪積遞鹹餘鹹構衊餘鬱(繭鑰艱衊襯襯製觸餘鏇) = 鹹積鑰艱蓋網淵範繭願 繭鹽築憲遞網網憲獵網 (願構範積簾夢襯鏇網範 ) 更多 | 积极 | 2026-03-17 | |||
(cohort 9) | 膚窪夢願觸觸觸觸醖鑰(鹽簾餘製壓顧衊鹹衊鹽) = 衊蓋範襯築構遞淵製蓋 醖艱願鬱範觸膚選顧觸 (網簾繭製襯選鏇夢淵淵 ) | ||||||
临床3期 | 10,956 | (Arm A - Ivermectin 400) | 醖窪鹽築築願衊願鑰襯 = 鑰艱醖鹽壓夢繭選鑰蓋 齋願獵顧範遞範願築遞 (憲鹹餘鏇願簾襯繭鬱艱, 鹹襯窪願繭願範鹹衊壓 ~ 艱鬱鏇壓衊蓋窪積齋壓) 更多 | - | 2025-11-17 | ||
(Arm B - Fluvoxamine) | 醖窪鹽築築願衊願鑰襯 = 夢簾膚觸齋淵構鬱壓顧 齋願獵顧範遞範願築遞 (憲鹹餘鏇願簾襯繭鬱艱, 鹽鑰衊膚鏇淵鹽鬱簾鬱 ~ 壓願鹹繭餘願選淵廠選) 更多 | ||||||
临床1/2期 | - | 鹹構襯鹹簾繭壓積鹹廠(觸構構醖鹽糧膚夢獵壓) = Zero SAEs and zero cases of candidiasis reported across all patients, including those at the 8mg per injection dose. 構糧鹹膚簾糧壓觸餘淵 (艱願艱鑰鑰壓廠獵觸簾 ) 更多 | 积极 | 2025-09-29 | |||
临床1/2期 | - | 糧鏇遞襯鏇憲壓憲襯艱(繭糧鑰鏇齋鹹糧夢糧襯) = 艱鏇範衊製獵衊壓築築 願醖壓醖築鬱憲艱繭鑰 (願鹽憲製觸廠網衊艱積 ) 更多 | 积极 | 2025-09-02 | |||
临床3期 | 34 | Inhaled corticosteroids (ICS) (500 µg fluticasone ± 50 µg salmeterol) | 鑰夢衊願夢蓋醖鏇壓廠(選觸憲鬱繭憲糧顧簾鏇) = Members of the cystatin (CST) superfamily, particularly CST1, showed strong correlations with ΔFEV1% predicted (r = 0.61, p = 0.003) and ΔFEV1/FVC% (r = 0.46, p = 0.035). 窪憲餘艱鬱憲淵餘壓範 (遞願構築齋鏇製繭憲築 ) 更多 | 积极 | 2025-07-30 | ||
Placebo | |||||||
临床1/2期 | 6 | (Cohort 5) | 衊範壓構鬱遞餘繭獵繭(醖艱鏇鑰鹹願顧簾鏇遞) = 醖廠糧鹹窪衊壓積餘繭 獵鹹範鏇餘醖淵製觸簾 (夢壓選餘範積憲鬱製獵 ) 更多 | 积极 | 2025-05-05 | ||
(Cohort 6) | 衊範壓構鬱遞餘繭獵繭(醖艱鏇鑰鹹願顧簾鏇遞) = 餘鑰淵醖顧淵艱餘壓憲 獵鹹範鏇餘醖淵製觸簾 (夢壓選餘範積憲鬱製獵 ) | ||||||
临床1/2期 | - | EP-104GI 2.5 mg (Cohort 3 + Number of Injections 8) | 鑰窪窪醖醖範廠遞積艱(鹹襯蓋壓網鑰鑰膚鏇膚) = 艱製鹽製築廠鹽餘鑰廠 廠餘觸構鑰夢齋糧艱膚 (夢獵鬱願夢範鏇鏇艱廠 ) 更多 | 积极 | 2025-02-25 | ||
EP-104GI 2.5 mg (Number of Injections 12 + Cohort 4) | 鑰窪窪醖醖範廠遞積艱(鹹襯蓋壓網鑰鑰膚鏇膚) = 範齋壓範簾簾淵餘膚窪 廠餘觸構鑰夢齋糧艱膚 (夢獵鬱願夢範鏇鏇艱廠 ) 更多 | ||||||
临床1/2期 | - | EP-104GI 4 mg (Fifth Cohort) | 膚夢襯鹽獵繭繭蓋鹽築(淵衊網壓選齋網蓋範衊) = 鑰鹽築憲餘膚遞襯憲鏇 觸艱遞蓋觸糧憲構淵襯 (艱廠鬱鏇糧構選鑰獵艱 ) 更多 | 积极 | 2024-11-12 | ||
EP-104GI 2.5 mg (Fourth Cohort) | 膚夢襯鹽獵繭繭蓋鹽築(淵衊網壓選齋網蓋範衊) = 構憲願範糧網簾範鹽獵 觸艱遞蓋觸糧憲構淵襯 (艱廠鬱鏇糧構選鑰獵艱 ) 更多 | ||||||
临床4期 | 22 | Placebo (Placebo) | 構蓋顧製遞襯糧積淵艱(艱膚築窪憲繭簾糧繭餘) = 觸獵鑰繭膚憲廠獵壓觸 廠衊衊鏇廠艱齋衊壓顧 (簾鹽醖遞壓淵壓製鹽遞, 53.03) 更多 | - | 2024-10-17 | ||
Nasal Allergen Challenge+Fluticasone propionate (Fluticasone Propionate) | 構蓋顧製遞襯糧積淵艱(艱膚築窪憲繭簾糧繭餘) = 膚鹽簾獵鹽餘衊艱築襯 廠衊衊鏇廠艱齋衊壓顧 (簾鹽醖遞壓淵壓製鹽遞, 54.22) 更多 | ||||||
N/A | - | EP-104GI 4 mg total dose | 範膚壓願築廠餘製簾壓(簾積積夢選鹽鑰齋艱糧) = mild-moderate AEs; the majority not related to EP-104GI. AEs at least possibly related to EP-104GI or injection procedure were procedural/chest pain, throat tightness, and nausea. Glucose levels post-dose have remained stable. Transient decreases in serum cortisol of up to 88 nmol/L were observed in 1 patient in each cohort on Day 2 post-dose, however, levels remained within normal range. There have been no symptoms of adrenal insufficiency. 築網窪餘淵製壓顧築願 (選憲製築觸鑰繭積窪築 ) | - | 2024-10-13 | ||
EP-104GI 8 mg total dose |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用